Abstract
Statins lower the risk of cardiovascular disease, yet may adversely affect glucose metabolism. In the D2d study, which evaluated the effect of vitamin D versus placebo in a contemporary cohort of people with high-risk prediabetes (n=2,423) , we evaluated the association between statin use at baseline and progression to diabetes. In the D2d study, 1396 participants (58%) were on statin at baseline. Kaplan Meier curves of incident diabetes over 2.5 years by baseline status of statin use and adjusted hazard ratio (95%CI) of the difference in incident diabetes between statin and no statin use were estimated. We tested for a statin use * D2d assignment (vitamin D or placebo) interaction on incident diabetes. Mean age (SD) was 57±years and 64±8 for those not on vs. on statin; baseline HbA1c was 5.9 ± 0.2% in both groups. 27% of statin users developed diabetes vs. 24% of non-statin users (adjusted HR [95%CI] 1.23 [1.04-1.46]) (Figure) . There was no significant interaction (p=0.67) with vitamin D treatment assignment; therefore, subgroup analyses by D2d treatment assignment are not presented. Conclusions: In this observational analysis among people at high risk for diabetes, baseline statin use was associated with a 23% higher risk of progression to diabetes after 2.5 years compared to no use. Increased risk of diabetes progression should be considered along with the cardiovascular benefits of statin therapy and diabetes prevention measures re-enforced. Disclosure J.Y.Park: None. A.Ghazi: None. A.G.Pittas: None. E.Vickery: None. J.P.Nelson: None. V.R.Aroda: Consultant; Applied Therapeutics, Fractyl Health, Inc., Novo Nordisk, Pfizer Inc., Sanofi, Other Relationship; Janssen Pharmaceuticals, Inc., Merck & Co., Inc., Research Support; Applied Therapeutics, Fractyl Health, Inc., Novo Nordisk, Sanofi. D2d research group: n/a. Funding American Diabetes Association (1-14-D2d-01) ; National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases and Office of Dietary Supplements (U01DK098245)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have